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Recent studies have demonstrated the clinical efficacy of psychedelic-assisted psychotherapy for
treatment-resistant depression and anxiety. Amidst the overall success of recent clinical trials
using a single high dose of psilocybin, anecdotal reports indicate anxiolytic and antidepressant
effects following a repeated low dose regimen. As therapeutic outcomes are often tightly
intertwined with the individual’s subjective experience, animal models are used as objective
measures to investigate the underlying mechanisms responsible for the putative
antidepressant/anxiolytic effects of psychedelics. Three rodent models predictive of anxiolytic or
antidepressant effects were used to evaluate effects of chronic intermittent low dose (CILD)
psilocybin treatment; the Light/Dark conflict test (L/D), an open field test (OFT), and the forced
swim test (FST). Rats were treated with vehicle or psilocybin (0.025, 0.05, 0.1 mg/kg) every 72
hours over a 48-day period. Tests were conducted 48 hours after the eighth injection (day 24)
(L/D, OFT), 48 hours after the 16th injection (day 48) (L/D, OFT, FST), and 12 days after the
last injection (day 58) (OFT, FST). Results from the current study indicate that CILD psilocybin
does not produce significant differences in exploratory, locomotor, or swimming behavior of rats
in the L/D, OFT, or FST paradigms. Rats administered 0.1 mg/kg psilocybin entered the light
compartment significantly sooner in the L/D test on day 48 than was observed on day 24.
Additionally, rats administered 0.05 or 0.1 mg/kg spent significantly more time in the center of

the open field apparatus on day 48 and/or 58 compared to time spent in center on day 24.
Measures of stereotypy from the OFT also varied within group, trending in the same direction
(reduced stereotypy counts) as saline control animals on day 48 and 58 suggesting that repeated
administration of low dose psilocybin does not appear to cause anxiogenic behavior. Overall, the
apparent lack of anxiolytic and antidepressant-like effects of CILD psilocybin in the present
study suggest that there may be distinct mechanistic and behavioral differences between subthreshold, “microdosing” of psychedelics and hallucinogenic high doses. Future studies with
more complex behavioral models, such as operant tasks, or ecologically representative rat
populations are warranted to further investigate the behavioral effects of CILD in rodents in
order to determine if the cognitive/behavioral effects of “microdosing” reported in humans is
exclusively a human phenomenon.
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INTRODUCTION
Depression and anxiety are two of the most prevalent psychiatric disorders worldwide
(Kessler et al., 2012) and a leading cause of disability (Substance Abuse and Mental Health
Services Administration [SAMSA] 2013; World Health Organization, 2017). The economic
burden of these disorders has been estimated to be over 200 billion dollars per year in the United
States (Greenberg et al., 2015). Global estimates project that by 2030 depression will be the
single most burdensome disease in terms of disability (World Health Organization, 2017). This
is due in part to the increased risk of absenteeism and decreased productivity in the workplace,
resulting in lowered income and unemployment (Broadhead et al., 1990; Whooley et al., 2002).
Treatment
Psychotherapy, broadly defined as an intentional treatment facilitated by skilled
professionals aimed to modify maladaptive thoughts, feelings, and behavior of individuals to
better one’s quality of life, has long been a core feature in the treatment of depression and
anxiety disorders (Lambert et al., 1994). Although evidence from meta-analyses have
demonstrated psychotherapy to be comparably efficacious to pharmacotherapy in the treatment
of depressive (Cuijpers et al., 2008; Speilmans et al., 2011) and anxiety disorders (Cuijpers et al.,
2013; Mitte, 2005), pharmacotherapy remains the predominant treatment for both disorders
(Ahrnsbrak & Stagnitti, 2020; Hockenberry et al., 2019; Olfson & Marcus, 2010).
Despite the widespread acceptance of mainstream antidepressant drugs, 40 to 60% of
patients remain inadequately treated (symptomatic) (Penn & Tracy, 2012). Some of the
limitations of current antidepressant drugs are: (1) delayed onset of clinical effects; (2)
substantial adverse medication effects that negatively impact continued treatment compliance;
(3) relatively small effect size in many responders; and (4) a high relapse and recurrence rate
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estimated to be 60% after 5 years, 67% after 10 years, and 85% after 15 years (Hardeveld et al.,
2010). The lack of treatment fidelity could be due to the co-occurrence (i.e., comorbidity) of
major depressive disorder (MDD) and generalized anxiety disorder (GAD). Epidemiological
studies indicate that over half of individuals diagnosed with MDD meet criteria for GAD (Carter
et al., 2001), making depression and anxiety the most prevalent comorbid mental health disorders
(Kessler et al., 2003). Comorbidity of MDD and GAD is strongly associated with poorer
prognosis (Hofmeijer-Sevink et al., 2012; Lamers et al., 2011), greater risk of recurrence of
depressive symptoms (Cyranowski et al., 2012) and higher risk for suicide (Nock et al., 2010). In
an effort to address some of the pitfalls of treatment-resistant depression, recent research has
begun to investigate alternative approaches, including psychedelic-assisted psychotherapy.
Psychedelics – Early History
Psychedelics, a term coined in the 1950s, refers to a multifarious subgroup of
hallucinogens that alter the human experience behaviorally, cognitively, and or psychologically,
primarily acting as agonists at serotonin 5-HT2A receptors in the brain (Halberstadt & Geyer,
2011). In other words, psychedelics increase serotonergic activity, which is associated with
happiness, emotional regulation, mood, and motivation (Baixauli, 2017).
Naturally occurring psychedelics have been used by humans for hundreds, if not
thousands of years. From the use of “sacred” mushrooms by Aztec shaman (Carod-Artal, 2015;
Ott & Bigwood, 1978), to ancient religious and spiritual rituals with ayahuasca (Banisteriopsis
caapi vines and Psychotriaviridis leaves) by tribes from the Amazon valley to the Andes
mountains of South America (Naranjo, 1986; Schultes & Hofmann, 1979), to the use of Peyote
(Lophophora williamsii) in Native American tribes of south and central America (El-Seedi et al.,
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2005), psychedelic plants have been a part of religious and healing practices predating written
accounts.
Despite the history of psychedelic use by humans, it was not until the scientific analysis
of the peyote cactus and isolation of the active component, mescaline, during the late nineteenth
century that scientific interest in the biological psychiatry of psychedelics truly began (Ellis,
1897; Lewin, 1894). Nearly half a century later, Albert Hofmann serendipitously discovered the
profound psychological effects of the semisynthetic 25th variation of Lysergic acid (Hofmann,
1979, p. 57-59). By the 1950s, Lysergic acid diethylamide (LSD) was readily distributed by
Delysid© Sandoz to the scientific community as a psychotomimetic (psychosis-like, temporary
psychosis inducing) drug to study schizophrenia in normal individuals (Hofmann, 1980, p. 59).
The psychotomimetic theory regarding LSD and mescaline did not persist for long, as evidence
emerged that the psychological state these substances induced was fundamentally different from
that of psychosis in schizophrenia (Stockings, 1940). Moreover, practitioners and scientists
began noting that psychedelics increased awareness, euphoria, and eventually improved certain
conditions at specific doses (Kurland et al., 1967; Pahnke et al., 1970; Stoll, 1947; Unger, 1969).
The British psychiatrist Humphrey Osmond was one of many practitioners who began
noting the clinical utility of psychedelics for psychiatric conditions beyond schizophrenia
(Chwelos et al., 1959). Beyond the theories, hypotheses, and scientific publications he
contributed, Osmond notoriously administered a dose of mescaline to the British novelist Aldous
Huxley, a year before Huxley published the infamous book, The Doors of Perception, an account
of Huxley’s personal psychedelic experience (Huxley, 1954). The relationship between Osmond
and Huxley had a transcending impact on the community. In fact, Osmond’s and Huxley’s
shared dislike for the term psychotomimetic led to the following infamous poem from

3

correspondence letters between the two of them in 1956: Huxley - “To make this trivial world
sublime, Take half a gramme of phanerothyme”; To which Osmond replied: “To fathom hell or
soar angelic, just take a pinch of psychedelic.” (as cited in Bisbee et al., 2018). Osmond provided
the scientific community with theories, hypotheses, evidence, and a felicitous word for such
mind-altering substances, but together with Huxley’s book, a manifesto for a generation was
provided, likely prompting the rise of the counterculture of the 1960s and ‘70s.
Word of the euphoric and mind-altering effects LSD, mescaline, and psilocybin,
successfully extracted from mushrooms in 1958 (Hofmann et al., 1958), spread far beyond the
scientific community and led to the “psychedelic movement” of the 1960s (Boskin &
Rosenstone, 1969; Lee & Shlain, 1985), which played a dynamic role in the counterculture
movement that questioned the social norms and values of Western culture.
Unfortunately, as scientific research on psychedelics continued to increase, so did the
recreational use of psychedelics, mainly LSD, which was widely popularized by the disaffiliated
Harvard psychologist turned celebrity, Timothy Leary (Lee & Shlain, 1985; Mansnerus, 1996).
Leary famously encouraged followers to “turn on, tune in and drop out” in reference to LSD
(Leary, 1967), which likely contributed to the rapid political divide and severe backlash in the
late 1960s (Boskin & Rosenstone, 1969; Dahlberg et al., 1968; Lee & Shlain, 1985; Mansnerus,
1996), and ultimately led to the demise of psychedelic research altogether (Hofmann, 1980).
Legal Status of Psychedelic drugs
Research with psychedelic substances was increasingly more difficult throughout the
1960’s and 1970’s. The Drug Amendments of 1962, which occurred in response to the
thalidomide tragedy, hindered continued research on all drugs, psychedelics included, largely
due to a proof-of-efficacy requirement and enhanced oversight of the U.S. Food and Drug
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Administration (FDA) (Drug Amendments of 1962). Additionally, the “war on drugs” initiated
by the Nixon administration, aided by negative media coverage of LSD in the U.S. led to the
Drug Abuse Control Amendments of 1965, which regulated the procession, manufacturing, and
sale of unlicensed stimulant, depressant, and hallucinogenic drugs (Drug Abuse Control
Amendments of 1965). By 1968, psilocybin and psilocin, the active metabolites of the psilocybe
mushroom, were specifically banned, followed by the Controlled Substance Act (CSA) of 1970
(effective May, 1971) that labeled psilocybin and psilocin as “hallucinogenic”, classifying them,
along with 15 other “hallucinogenic substances”, as schedule 1 substances, declared to have “a
high potential for abuse”, “no currently accepted medical use” and “lack of accepted
safety…under medical supervision” (Comprehensive Drug Abuse Prevention and Control Act of
1970).
Although some research with psychedelics continued into the 1970’s (Nichols & Walter,
2020), much of the damage had already been done, as noted by Dahlberg and colleagues in a
1968 study which suggested that the virulent publicity of LSD (up to the end of 1966) negatively
impacted the recruitment, quality, and attitudes of participants, as well as the behavior of
research and hospital personnel.
Reemergence of Psychedelic Research
After nearly three decades of almost complete abandonment of psychedelic research,
researchers began revisiting theories and findings from research of the 1940-60’s to
systematically, and ethically reevaluate the once promising effects of psychedelic compounds.
Psilocybin, a naturally occurring alkaloid derived from L-tryptophan, a tryptamine, found in
some mushrooms, once overshadowed by LSD research, reemerged from the ashes and was
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reestablished by clinical scientists as a viable treatment option for several psychological
disorders.
The reemergence of psilocybin over LSD may be due in part to the enmity and
stigmatization left by LSD in the 1960s and ‘70s (Dahlberg et al., 1968; Hofmann, 1980).
Additionally, psilocybin bypassed legal restrictions in several countries where LSD did not,
largely due to religious practices and nuances in legislation, making the substance easier to
acquire and study (Andersson et al., 2009; Controlled Drugs and Substances Act; Religious
Freedom Restoration Act). Nonetheless, recent psilocybin research has demonstrated that
psychedelic-assisted psychotherapy could engender significant reductions in depression and or
anxiety scores in human populations (Carhart-Harris et al., 2016; Grob et al., 2011; Rucker et al.,
2016). Several researchers observed a reduction in depressive symptoms that persisted up to 6months post psilocybin-assisted therapy sessions (Carhart-Harris et al., 2018; Griffiths et al.,
2016; Ross et al., 2016).
Not only does psilocybin appear to have sustained effects that last months after a session,
but an open-label trial with individuals with moderate-to-severe treatment-resistant depression
found that a single low dose of psilocybin (10 mg) followed by a high dose (25 mg) seven days
later reduced symptoms of depression as soon as one week after the second (last) treatment
(Carhart-Harris et al., 2016). Although the onset of action of typically prescribed antidepressants
varies among specific drugs and symptoms, clear therapeutic effects generally require roughly
two to four weeks of daily use (Puech et al., 1997; Stassen et al., 1993, 1996; Uher et al., 2011).
In the U.S., the average length of inpatient hospital stays among individuals with serious mental
health diagnosis is roughly 9-10 days (Lee et al., 2012; Watanabe-Galloway & Zhang, 2007),
with hospital stays even shorter for uninsured patients (Lee et al., 2012). Therefore, the utility of
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psilocybin may extend beyond the sustained effects noted in clinical studies and may address the
issue of delayed onset of action, a current barrier with standard pharmacological treatment of
depression (Jick et al., 2004)
The recent success of psychedelic-assisted psychotherapy has been accompanied by
supportive media, public, and scientific attention (Fadiman, 2011; Gregoire, 2016, Oaklander,
2017), which has likely influenced the recent decriminalization of psilocybin in several cities
across the U.S. (Marks, 2020; Office of Attorney General, 2019) and the statewide legalization
of psilocybin for therapeutic use in Oregon (Measure 109: Psilocybin Service Act, 2020).
Prevalence of Recreational Use
Despite psychedelic substances remaining classified as schedule 1 drugs by the Drug
Enforcement Agency (DEA), 17% of adults 21-64 have reported using LSD, psilocybin, or
mescaline/peyote at some point in their life (Krebs & Johansen, 2013), with roughly 6.0 million
individuals aged 12 and older reporting hallucinogen use in the past year (Substance Abuse and
Mental Health Services Administration, 2020). Additional data from national drug use surveys
estimated that 8.8-10% of adults aged 18 and older reported using psilocybin in their lifetime
(Center for Behavioral Health Statistics and Quality, 2019; Yockey & King, 2021). Moreover,
the use of psilocybin in particular has increased since the 1970s across the US and worldwide,
likely due to increased legality due to religious exceptions and ease of at-home cultivation
techniques (Andersson et al., 2009).
Microdosing
Psychedelic use among individuals generally involves a substantial dose of a substance
that typically causes profound perceptual changes, often referred to as hallucinations, though not
to be confused with hallucinations associated with psychiatric disorders. Recently, psychedelic
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use in the form of microdosing has become increasingly popular worldwide (Solon, 2016;
Waldman, 2018). Microdosing refers to repeated intermittent use of sub-hallucinogenic/threshold
doses. In fact, 17% of responders from an anonymous online survey on recreational drug and
alcohol use reported to have microdosed. Psilocybin was reported to be the second most common
drug to microdose (26.18%) after LSD (48.58%). Interestingly, military veterans were among the
most likely to microdose, not individuals in the tech industry as anecdotal reports suggest
(Cameron et al., 2020). Of those who reported to microdose with psychedelics, the subjective
effects of microdosing were attributed to enhanced mood, decreased depression and anxiety,
improved memory, attention, and sociability (Anderson et al., 2019b; Cameron et al., 2020).
Anecdotal reports and surveys of the subjective effects of microdosing with psychedelics
suggest that large, full doses of psychedelics may not be necessary to improve behaviors
associated with depression and anxiety. To date, only one double-blind, placebo-controlled study
assessed the effects of microdosing, and did not find any effect of LSD microdoses on
perception, mentation, or concentration (Yanakieva et al., 2019). Interestingly, an open-label
study assessing the effects of microdosing with psilocybin found that performance was improved
in several, but not all cognitive assessments. Specifically, psilocybin microdoses improved
divergent and convergent thinking but not fluid intelligence (Prochazhova et al., 2018),
suggesting that creativity and cognitive flexibility may be enhanced after microdosing. The
findings of the aforementioned study suggest that low, sub-threshold psilocybin doses may
facilitate cognitive flexibility similar to that noted in full-dose trials (Carhart-Harris et al., 2014,
2016).
The promising effects of psilocybin microdosing provide a new potential avenue for
treating depression and anxiety in individuals when a full-dose may not be desired. Although
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psilocybin has a relatively low risk for abuse or harmful effects (Johnson et al., 2018; Stone et
al., 2007), some risks are associated with large doses, mainly for those with preexisting
conditions (Hasler et al., 2004; Nielen et al., 2004). Additionally, a percentage of individuals
require additional psilocybin treatment sessions after the initial psilocybin dose (Carhart-Harris
et al., 2018). Individuals who require multiple full-dose treatments for continued remission of
depressive symptoms and anxiety may benefit from chronic administration of low-dose
psilocybin.
Psilocybin Neuropharmacology
Most serotonergic psychedelics fall into one of three classes: lysergamides (e.g., LSD),
phenethylamines (e.g., mescaline), and tryptamines (e.g., psilocybin and DMT) (Halberstadt,
2015; Nichols, 2016; Snyder & Richelson, 1968). Psilocybin (4-phosphoryloxy-N,Ndimethyltryptamine) is naturally occurring monoamine alkaloid (indolealkylamines) derived
from the amino acid tryptophan. Naturally occurring tryptamines are found in a variety of plants
and life forms (Hofmann, 1968; Schultes & Hofmann, 1979; Wurst et al., 2002), including the
endogenous neurotransmitter, serotonin (5-hydroxytryptamine) (Chilton et al., 1979), and the
psychoactive fungi referred to as “magic mushrooms” (Schultes & Hofman, 1980). Over 140
hallucinogenic mushrooms contain psilocybin and/or psilocin as the primary psychoactive
metabolite(s) (Guzman et al., 1998; Guzman, 2005). Psilocybin itself is a prodrug, biologically
inactive, that is metabolized into the pharmacologically active compound psilocin (4-OHdimethyltryptamine) (Hofmann, 1968) which crosses the blood brain barrier primarily binding at
5-HT2A receptors, and 5-HT1A to a lesser extent (McKenna et al., 1990). Furthermore, ketanserin,
a selective 5-HT2A receptor antagonist, blocks the psychotomimetic effects of psilocybin
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suggesting that it acts as a selective 5-HT2A receptor agonist (Quednow et al., 2012;
Vollenweider et al., 1998).
The structural similarity of psilocybin/psilocin to serotonin is likely what leads to its high
affinity for the serotonin neurotransmitter system, in turn producing profound changes in sensory
perception, mood, and thought, leading to hallucinations (Chilton et al., 1979; Schultes &
Hofmann, 1980). Although, nearly all hallucinogenic compounds demonstrate a high affinity for
5-HT2A receptors (Gonzalez-Maeso et al., 2007; McKenna et al., 1990), not all 5-HT2AR agonists
have hallucinogenic activity (Pieri et al., 1978), suggesting that psilocybin may elicit some of its
effects through the activation of secondary messengers and systems.
While hallucinogenic and non-hallucinogenic 5-HT2R agonists both act on the same
cortical neurons, the differing behavioral responses hallucinogenic compounds exert may be due
to unique patterns of signaling in cortical neurons. A study using genetically modified mice
found that hallucinogenic 5-HT2AR associated responses were caused by the regulation of
upstream pathways and not alternations in gene expression itself. Specifically, activation at 5HT2AR by LSD was associated with unique G protein-dependent signaling from that of Rlisuride, a non-hallucinogenic 5-HT2AR agonist (Gonzalez-Maeso et al., 2007). Moreover,
hallucinogen-specific signaling and behavioral responses were eradicated when the metabotropic
glutamate receptor, mGluR2, was activated (Gonzalez-Maeso et al., 2008). Nonetheless, the
neuroprotective effects of psilocybin are attributed to 5-HT2AR activity (Vollenweider &
Kometer, 2010).
Psilocybin and Brain Mechanisms of Emotion Regulation
The cortex, ventral striatum, hippocampus, amygdala, and their corresponding circuits
modulate behavioral responses to both novelty and threat, common indices of anxiety. These
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same structures are abundant in 5-HT2AR expression. In particular, the role of serotonergic
neurotransmission in the amygdala, a brain region well established for its role in emotion
processing, is known to have an active part in the development and presentation of MDD and
anxiety (Drevets et al., 2002; Pezawas et al., 2005; Victor et al., 2010). Considering the
serotonergic modulation of psilocin and psilocybin and the robust clinical effects of psilocybinassisted therapy on emotional and mood regulation in individuals suffering from depression
and/or anxiety (Carhart-Harris et al., 2014, 2016; Davis et al., 2021; Griffiths et al., 2016; Grob
et al., 2011; Rucker et al., 2016), unsurprisingly psilocybin was found to attenuate amygdala
activation to fear-induced tasks in an fMRI study. Specifically, psilocybin-induced reductions in
amygdala activation to negative and neutral stimuli were associated with increased positive
mood state, without increased anxiety (Kraehenmann et al., 2015), suggesting that psilocybin
may dysregulate/inhibit hyperactivity of the amygdala, a common marker in MDD and anxiety,
through modulation of the serotonergic systems.
Preclinical Behavioral Assessments of Psilocybin
Despite recent clinical outcomes and favorable public attention regarding the use of
psychedelics for treatment resistant depression/anxiety, few studies have investigated
mechanisms underlying the potential psychotherapeutic effects of these drugs, particularly in
regards to chronic intermittent low-dose (CILD) use. Preclinical (animal) studies are frequently
used to assess the underlying mechanisms, such as receptor activity and function, responsible for
the therapeutic effects of psychiatric medications. Rodent models of depression are mainly based
on predictive validity, objectivity of measured response and their high reliability and
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reproducibility. Such investigations are also aimed at the development of safer and/or less toxic
alternative medications.
Several unconditioned behavioral responses have been observed in the assessment of the
hallucinogenic properties of psilocybin. Acute administration of psilocybin has been found to
cause changes in the head-twitch response (HTR), acoustic startle reflex, anti-anhedonic
responses (Hesselgrave et al., 2021), elevated plus maze (EPM), locomotion, exploratory
behaviors, and escape behaviors (Jones et al., 2020). Although many animal models predictive of
anxiety and depression exist, only one model predictive of the hallucinogenic effects, three
unconditioned anxiety tests, and one model of depression will be discussed in depth. Models
discussed herein were selected based on recency, prevalence, validity, and applicability to the
current study’s objective in the assessment of anxiolytic and depressive-like behaviors of
psychedelic substances in rodents.
Head Twitch Response. Serotonergic psychedelics elicit a head-twitch response (HTR),
rapid rhythmic lateral rotations of the head, normally absent in rodents, that is highly predictive
of the hallucinogenic effects of compounds in humans (Halberstadt & Geyer, 2013: Halberstadt,
et al. 2020). Psychedelics produce HTR in rodents through activation of the 5-HT2A receptor,
which is responsible for the hallucinogenic effects of psychedelic substances in humans
(Kometer et al., 2013; Quednow et al., 2012). The HTR reliably differentiates between nonhallucinogenic and hallucinogenic 5-HT2A receptor agonists (Gonzalez-Maeso et al., 2007).
Duration and time course of HTR has additionally been utilized to establish hallucinogenic-like
time-points in rodents. Psilocybin was found to increase HTR in mice in the 10 minutes after a
single 3 mg/kg dose of psilocybin. The head twitch response was non-evident two hours after
drug administration (Jones et al., 2020).
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Preclinical Anxiolytic Screening
Elevated Plus Maze. Experimental models for the evaluation of anxiety-like behaviors in
rodents often use conflict situations in which the animal must engage in ethologically conflicting
behaviors. The elevated plus maze test is a commonly employed apparatus to assess
anxiolytic/anxiogenic properties of drugs and the neurobiological mechanisms of anxiety.
Rodents are placed on an elevated platform consisting of two open arms intersected by two
enclosed arms (plus). Rodents typically display a natural avoidance of open and elevated spaces;
this conflicts with the species' natural tendency to explore novel environments (Briley et al.,
1990; Cruz et al., 1994; Montgomery, 1955; Rodgers et al., 1997). Anxiolytic drugs increase the
time spent and number of entries into the open arms, whereas anxiogenic substances and
stressors produce the opposite effect (Pellow et al., 1985; Pellow & File, 1986; Rodgers & Cole,
1993).
Light/Dark Box (L/D) Test. Similarly, the light/dark box test was developed by Crawley
and colleagues as an approach-avoidance conflict situation in which exploration of novel
environments is met with the conflicted species-specific behavior to avoid brightly lit open
spaces (Crawley & Goodwin, 1980; Crawley, 1985). Anxiolytic drugs increase the amount of
time spent in the light compartment and distance traveled in the light compartment (Chaouloff et
al., 1997; Young & Johnson, 1991). It is important to note that the number of transitions between
the light and dark compartments is highly correlated with other exploratory behaviors but is not
correlated with locomotor activity.
Open Field Test (OFT). The open field test was initially developed to measure
locomotor activity and exploratory behavior in rodents (Hall & Ballachey, 1932). Similarly to
the L/D test, OFT is referred to as a test of unconditioned anxiety due to the nature of the test
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which places the rodent in a novel open space. The biological predisposition of rodents
stimulates an avoidance response, not previously conditioned. Anxiolytic drugs such as GABAA
benzodiazepine receptor agonists such as chlordiazepoxide and diazepam decrease the number of
crossings, rearing, stretching, and thigmotaxis (wall-following) in the OFT (Choleris et al.,
2001), confirming the anxiety-provoking value of the OFT.
Preclinical Antidepressant Screening
Forced Swim Test (FST). The most commonly employed preclinical model of
depression, the forced swim test, was originally developed by Porsolt and colleagues in 1978.
The premise of the FST is that when rodents are placed in a cylinder filled with water they will
engage in escape related behaviors to thwart the threat of drowning. Since rodents are placed in
an inescapable environment, escape-directed behaviors are not reinforced and therefore begin to
dissipate after a period of time resulting in passive immobile behavior said to resemble
behavioral despair (Porsolt et al., 1978). The original FST was instrumental in the preclinical
assessment of most antidepressant drugs (Borsini & Meli, 1988; Lucki, 1997), with the exception
of SSRIs (Borsini, 1995). Lucki et al., (1994) developed a modified version of the FST that
allowed for more reliable detection of SSRIs (Cryan et al., 2005; Detke & Lucki, 1995).
Additionally, the modified FST allows for the identification of predominant neurotransmitter
system activation by novel pharmacological agents and differentiates the two main active
behaviors, climbing and swimming from one another (Detke et al., 1995; Page et al., 1999;
Reneric & Lucki, 1998; Slattery et al., 2005), which allows for more specific characterization of
antidepressant-like effects. For example, antidepressant drugs that inhibit norepinephrine
reuptake were found to reduce immobility and increase climbing without affecting swimming
(Page et al., 1999; Page et al., 2003), compared to selective serotonin reuptake inhibitors that
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were observed to reduce immobility but increase swimming without affecting climbing (David et
al., 2003).
Preclinical Assessment of Single High Dose Drug Effects
Similar to results from clinical trials, a single dose of psilocybin (1.0 mg/kg) produced
persistent anxiolytic and antidepressant-like effects in Wistar-Kyoto rats assessed in the FST and
EPM. Rats administered psilocybin on day 0 demonstrated a significant reduction in immobility
and an increase in swimming behavior compared to saline controls when assessed in the FST
multiple or a single time, one, two, three, four and five weeks after treatment (see Hibicke et al.,
2020). Although all three groups of rats administered psilocybin displayed significant reductions
in immobility counts compared to saline five weeks post-injection (day 35), rats that only
underwent FST once (day 35) displayed slightly stronger significant differences in immobility
from saline (p < 0.0001) compared to the other two groups (PSI, p < 0.05; rPSI, p < 0.005).
Interestingly, six weeks following a single dose (day 41) of psilocybin, EPM measures in rats
exposed to the FST once were not statistically different from those of the corresponding saline
controls, yet the two groups of rats that underwent the FST multiple times spent significantly
more time in the open arms and less time in the closed arms of the EPM, indicative of an
anxiolytic response, compared to saline control rats (Hibicke et al., 2020). Hibicke et al. (2020)
suggest that the observed difference in EPM behavior among treatment groups could be related
to a similar phenomenon observed following psychedelic use among humans referred to as “set
and setting” (Leary et al., 1966). Typically, the notion behind “set” pertains to the “mindset” an
individual has in regards to prior experiences, traumas, fears, and attitudes toward the substance,
during or immediately before the psychedelic-therapy session. “Setting” refers to the space and
environment in which one experiences the drug effects (Johnson et al., 2008; Olson et al., 2020;
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Strickland et al., 2020). In regards to the study by Hibicke et al. (2020), it is possible that the
one-time psilocybin dose combined with repeated exposure to the open field arena where
locomotor activity was recorded, weekly, in the two groups that underwent FST multiple times,
increased a type of passive learning or coping strategy as similarly noted in MDMA-treated mice
in a model of social reward learning (Nardou et al., 2019).
Results from behavioral models of anxiety and depression in rodents are equivocal. A
study conducted in Flinders Sensitive line (FSL) rats failed to find a significant effect of
psilocybin or psilocin administration on immobility, swimming, or struggling behavior compared
to saline controls (Jefsen et al., 2019). Distinct methodological differences are notable between
the aforementioned study by Hibicke et al. (2020) and the Jefsen et al. (2019) study with FSL
rats. Flinders sensitive line rats express altered gene expression relevant to glutamatergic and
serotonergic signaling that may not be conducive to assessing the effects of psilocybin or FST,
both of which implicate the involvement of 5-HT2A receptor mediated activities (Cryan et al.,
2005; McKenna et al., 1990; Page et al., 1999; Quednow et al., 2012; Vollenweider et al., 1998
). While the reduced expression of 5-HT2A receptors and increased mRNA expression of 5-HT2c
and mGlur2 (Du Jardin et al., 2016) may have high utility in assessing the antidepressant and
anxiolytic effects of NMDA receptor antagonist, ketamine (Du Jardin et al., 2017, 2018), the
reduction of hippocampal and prefrontal cortex 5-HT2A expression may deem the FSL an
inappropriate animal strain to assess the effects of psilocybin and psilocin. More importantly, the
study by Jefsen and colleagues assessed the effects of psilocybin and psilocin in OFT and FST
either 4 h or 24 h after a single dose, or eight days after three injections (once daily) (Jefsen et
al., 2019). Considered together with findings from Hibicke et al. (2020) and two spatial memory
tests with rats given similar psilocybin doses (Rambousek et al., 2014), it is possible that the
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behavioral effects of psilocybin in the OFT and FST are not apparent until 48 h after
psilocybin/psilocin administration.
Assessment of Chronic High Dose Drug Effects
Although psilocybin appears to have a large safety margin in terms of negative
physiological and psychological effects (Johnson et al., 2008; Nichols, 2004; Studerus et al.,
2011), several reports have indicated that long-term intermittent high dose use with psychedelics
such as ayahuasca, and LSD, is associated with neurodegeneration in the posterior cingulate
cortex in humans (Bouso et al., 2015) and neuroadaptations of the serotonin and dopamine
transport systems associated with increased anhedonia, locomotor activity, aggression, and social
deficits in rodents (Marona-Lewicka et al., 2011). Such behavioral changes are associated with
changes in gene expression in the prefrontal cortex that are negatively associated to neural
plasticity (Vaidya et al., 1997). Interestingly, when LSD was administered at 0.13 mg/kg every
day for 11 days vs 0.16 mg/kg every other day for three months, LSD led to recovery of
avoidance learning in olfactory bulbectomised rats (Buchborn et al., 2014; Marona-Lewicka et
al., 2011).
While a single moderate to high dose administration of a psychedelics, such as LSD or 4iodo-2,5-dimethoxyphenylisopropylamine (DOI), a 5-HT2A/2C receptor agonist, increased neural
plasticity related gene expression (Nichols & Sanders-Bush, 2002; Vaidya et al., 1997), chronic
high dose use downregulated brain derived neurotrophic factor (BDNF) mRNA in the rat
hippocampus after 2 mg/kg DOI was administered for seven days (Vaidya et al., 1997).
Together, these disparate results among studies suggest that both dose and total duration of drug
administration affect behavioral and neural effects of psychedelic substances.
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Assessment of Chronic Intermittent Low Dose (CILD) Drug Effects
Much behavioral research on psilocybin in animal models of depression and anxiety have
focused on acute administration and assessment of a limited number of moderate to high doses.
Given the divergent results among studies that have been conducted with psychedelics at various
doses, dosing schedules, along with the increased popularity of “microdosing”, mostly due to its
anecdotal reports ( Ultimate Guide to Microdosing Mushrooms , n.d.; Waldman, 2018),
researchers have begun to investigate the effects of chronic, intermittent low-dose (CILD)
psychedelic use. Anecdotal and self-reports of the subjective effects of microdosing suggest a
positive increase in emotion, mood, and cognition is immediate and sustained (Anderson et al.,
2019b; Cameron et al., 2020; Ultimate Guide to Microdosing Mushrooms, n.d.; ; Waldman,
2018).
While placebo-controlled studies are essential to determine the precise effects of
microdosing with psychedelics on a wider range of cognitive functions, preclinical assessments
can provide objective measurements that are free from subject bias and placebo effect. If sub
perceptual doses of psilocybin are found to produce anxiolytic, antidepressant, or increase
cognitive flexibility, as subjectively reported, it would suggest that the altered state of
consciousness which requires seven to eight hours of one-on-one therapeutic oversight (Yaden et
al., 2021) may not be necessary to promote the positive neurobiological changes associated with
psychedelic use (Hasselgrave et al., 2021; Jefsen et al., 2021; Nichols & Sanders-Bush, 2002).
To date, few studies have investigated the effects of microdosing with psychedelics in
preclinical animal models of depression and anxiety. Of the studies that examined CILD with
psilocybin, subchronic psilocybin administration, three doses over six days (0.05 or 0.075
mg/kg), did not produce anxiolytic effects in the EPM. Though the main effect of drug treatment
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was not significant [F(2, 21) = 2.02, P= 0.07], the mean number of open arm entries was reduced
for 0.05 mg/kg, and statistically significant when analyzed with a one-tailed t-test [t(14) = 1.87,
P< 0.05]. A reduction in time spent in open arms and closed arms was significant [F(2, 21) =
2.60, P<0.05]. Contrary to open arm entries, independent t-tests found that the higher dose
(0.075 mg/kg) increased the percentage of time spent in closed arms and corresponded with
decreased percentage of open arm time, while the lower dose (0.05 mg/kg), did not, although
trended in a similar fashion (Horsley et al., 2018). As the main measure of anxiety in the EPM is
the number of entries into the open arms, the results suggest that subchronic low doses of
psilocybin directly oppose the anxiolytic effects seen after a single high dose in the EPM
(Hibicke et al., 2020), and may even have an anxiogenic profile.
Results from the aforementioned study should be considered with caution as the CILD
dosing regimen consisted of only three drug injections, which does not mimic microdosing
patterns reported by users (Fadiman, 2011; Johnstad, 2018; Polito & Stevenson, 2019; Ultimate
Guide to Microdosing Mushrooms, n.d.). Additionally, anxiety-like behaviors were measured in
one behavioral test, and EPM was conducted 48 hours after the last dose. Not only has EPM
been scrutinized for its weak and inconsistent effects with serotonergic antidepressants, but
previous reports suggest that the acute effects of psilocybin in spatial memory tasks were still
present beyond suspected drug clearance (24 h) (Rambousek et al., 2014). Anxiolytic effects of
psilocybin may be delayed beyond a week (Hibicke et al. 2020). Identification of viable
behavioral tests to assess the effects of CILD psychedelics is of the utmost importance in order to
appropriately determine anxiogenic, anxiolytic, or antidepressant effects.
A study by Cameron et al. (2019) assessed CILD N,N- dimethyltryptamine (DMT) across
a host of behavioral paradigms, along with cellular quantifications and determined that some
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tests may be more efficacious than others in the assessment of CILD psychedelic use. N,Ndimethyltryptamine DMT is the core structure in many indole psychedelics, including psilocybin
(Snyder & Richelson, 1968), which suggests that tests found to be sensitive to the CILD effects
of DMT would extend well to other similar psychedelics. Researchers assessed the effects of low
dose DMT (1 mg/kg), injected every three days for a total of 16 injections over the course of two
months. This dose is postulated to be “sub-perceptual” [10% of a hallucinogenic dose of DMT
previously evaluated (Cameron et al., 2018)]. Chronic, intermittent low dose DMT did not
produce anxiogenic or anxiolytic behaviors on novelty-induced locomotion (NIL) or exploratory
and locomotor behaviors captured in the EPM. While DMT did not affect contextual fear or
formation of cue induced fear memory, DMT-treated animals did display reduced freezing
behaviors compared to vehicle controls, demonstrating that DMT enhanced fear extinction
learning. Moreover, DMT-treated animals exhibited antidepressant-like effects in the FST.
Specifically, DMT-treated animals spent less time immobile and more time swimming than
vehicle controls, and did so without an increased locomotor response in the OFT, which suggests
that the increase in active coping strategies and decrease in “despair” seen in FST were not due
to increased locomotor activity (Cameron et al., 2019).
Aims and Objectives of the Present Study
The aim of the current study was to evaluate the behavioral effects of chronic intermittent
low dose treatment with psilocybin in established preclinical assessments predictive of
traditional anxiolytic and antidepressant drug effects The following tests were implemented to
explore the potential anxiolytic and/or antidepressant effects of chronic intermittent low-dose,
sub-threshold, psilocybin treatment: (1) Light/Dark Box (L/D), a behavioral model of anxiety in
rodents; (2) an Open field task (locomotor assessment) (OFT), a commonly employed animal
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model that tracks activity, movement and exploratory behaviors; and (3) a forced swim task
(FST), one of the most commonly employed paradigms to measure depressive-like behaviors in
rodents and said to resemble “behavioral despair” (Porsolt et al., 1977).
To the authors' knowledge, the effects of CILD administration of psilocybin have not
been investigated in the aforementioned paradigms over a two-month period. The primary aim of
the study was to implement a CILD pattern that mimicked dosing regimens reported by humans,
and to assess if psilocybin differentially affects locomotor or exploratory behaviors in two
conflict models of anxiety, and active vs passive coping in a behavioral model of depression in
rodents. A second aim of the current study was to assess if a chronic intermittent dosing schedule
of psilocybin would increase anxiolytic or depressive behaviors in rats over time. Chronic
administration of LSD was found to increase stereotypy, locomotor activity, anhedonia, and
decrease social interaction in rats treated for three months (Marona-Lewicka et al., 2011).
Therefore, the present study assessed behavior in the L/D and OFT halfway through the dosing
regimen (8 injections over the first month) and again with FST after the 16th injection (~2
months). Lastly, OFT and FST were conducted one additional time, two weeks after the last
injection to determine if behavioral effects persisted.
Predicted Outcomes
It was expected that CILD psilocybin would decrease latency to enter the light
compartment, increase time spent in, entries to, and exploration in the light compartment,
compared to saline controls. Secondly, psilocybin-treated rats would spend proportionally more
time in the center of the OFT than in the perimeter of the open field, without impacting overall
locomotor activity. Psilocybin treated rats were expected to spend less time immobile and more
time engaging in active behaviors (swimming, climbing, etc.) compared to saline-treated rats.
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The effects from the OFT and FST were expected to persist to the last set of tests performed on
day 58 (12 days post final injection). Lastly, the effects of CILD psilocybin were observed at
multiple time points during the study (day 24, 48, and 58) to assess if changes in behavior
(positive or negative) were dependent on the number of chronic intermittent doses.

METHODS
Subjects
All experiments were performed in compliance with the Guide for the Care and Use of
Laboratory Animals (2011) and were approved by the Institutional Animal Care Use Committee
at Western Michigan University. Forty-eight male Sprague-Dawley rats (approximately 30 days
old) purchased from Charles River Laboratory (Wilmington, MA) were pair-housed in
polycarbonate cages with corncob bedding in a temperature (21-23 ºC), humidity (30-50%)
controlled environment and maintained on a 12:12 hour light dark cycle (lights on at 0700 and
off at 1900 hours) with ad libidum access to food and water. Rats were between 51 and 54 days
old at the start of drug injections and finished the last set of behavioral tests between 109-112
days, comparable to previous FST studies (Cameron et al., 2019; Hibicke et al., 2020) and within
the recommended window for reliable forced swim behavior (Turner et al., 2012).
Subjects were randomly assigned to one of the following treatment groups: (a) Saline
(n=12); (b) Psilocybin 0.025 mg/kg (n=12); (c) Psilocybin 0.05 mg/kg (n=12); (d) Psilocybin 0.1
mg/kg (n=12). Injections occurred between 11:00 and 13:30 h and behavioral tests occurred
between 10:00 and 16:00 h. All rats underwent behavioral tests in the same order (L/D test, OFT,
FST).

22

Drug
Psilocybin was provided by the National Institute on Drug Abuse (NIDA) drug control
supply (Bethesda, MD, USA). Bacteriostatic sodium chloride (0.9%) (saline) was used as the
vehicle for psilocybin. A single injection of sterile saline or psilocybin in saline vehicle was
administered in a volume of 1 mg/kg intraperitoneally (IP) to each rat on treatment/injection
days. Doses and route of administration were selected based on previous literature (Cameron et
al., 2019; Hibicke et al., 2020; Horsley et al., 2018). Schedule of drug administration was guided
by previous literature (Cameron et al., 2019; Hibicke et al., 2020) and a pilot study previously
conducted in the same laboratory setting.
Apparatus and Behavioral Tests
Light/Dark Conflict Test (L/D). Behavioral assessments in the light/dark box were
conducted in six identical, two compartment place preference chambers (MED-CPP2-RS, MED
Associates INC, St. Albans, VT) equipped with a manual door which provides an 8 cm x 8 cm
opening between the two compartments allowing the rat to move between chambers. One
compartment contained black walls, steel rod floor, and no direct light (i.e. the dark box), while
the other compartment consisted of white walls, mesh flooring, a built-in 60 lux light located on
the lid of the apparatus and an additional light situated above the lit compartment (i.e. the light
box). Illumination within the dark box was negligible (i.e. < 50 lux) with the light compartment
calibrated to 350 lux more than that of the dark compartment. Six infrared sensors in each of the
two chambers monitored location and movement of animals. Entries and time spent in each
compartment were recorded with Med-PC version IV software (Med Associates, Inc., St. Albans,
VT) for the total five minute duration of the L/D test session. Additionally, total distance
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traveled in the light and in the dark compartments, total distance traveled, and the percent of total
distance traveled in the light compartment were recorded. Latency to enter the light box was
video recorded and later manually calculated by an experimenter blinded to group assignment.
Open Field Test (OFT) – Locomotor Activity. The open field test was used to assess
rodent activity and movement. Rats were individually placed in an open field test chamber (40
cm x 40 cm x 40 cm) for 60 minutes for the first OFT exposure, and 30 minutes for subsequent
tests (decided upon after analysis of behavior from initial OFT exposure). Open field tests
provide an index of anxiety-like behavior and general activity of animals. Drug-induced
increases in time spent in the peripheral regions of the open field (thigmotaxis, clinging to walls
and corners) is considered an index of anxiogenic effects, whereas increases in time spent in the
center of the open field is an index drug-induced anxiolytic effects. Additionally, OFT was
conducted immediately prior to each FST to monitor locomotor activity to control for any
sedative or stimulant effects that might confound results. Increased or decreased locomotor
activity in the FST is only meaningful if locomotor activity in the OFT remains unchanged.
Lastly, stereotypy counts were calculated as repetitive beam breaks and reported since a concern
of chronic psychedelic use is the development of psychotic features. Stereotypy refers to
repetitive non-functional behavior which has been used as a measure of psychosis in both
humans and in animal models of psychosis (Andine et al., 1999; Fetsko et al., 2003; Hitri et al.,
1993). Horizontal and vertical infrared beams located in each chamber were connected to a
computer programmed with software to track the activity and movement of each rat (Accuscan
Instruments, Inc., Columbus, OH).
Forced Swim Task (FST). The forced swim test, a commonly employed predictive
model of depression in rodents, was used to measure depression-like behaviors 48 h following
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chronic administration of psilocybin or saline. Rats were placed in one of six glass cylindrical
tanks (46 cm × 20 cm) filled to a 30 cm depth with water 24 ± 1ºC for 15 minutes during preexposure session (24 hours before FST test), and for five minutes during FST test. Black
cardboard dividers were used to separate swim tanks from one another and provide a contrasting
background to more easily distinguish the behavior of the rats when coding. Water was changed
between individual test sessions to reduce any influence of scents between rats. Upon removal
from the water, rats were towel dried by the experimenter and placed into polycarbonate cages
with a heating pad. Video cameras were used to record the five-minute swim tests, which were
scored at a later time for swimming, climbing, and immobility. Swimming was defined as
horizontal movements throughout the swim cylinder, which included crossing into other
quadrants. Rare instances when rats dove down to the bottom of the cylinder were scored as
swimming activity. Climbing activity (sometimes referred to as thrashing) consisted of upward
directed movements of the forepaws along the side of the swim chamber. Immobility was scored
when the rat appeared to be floating in the water with no additional activity other than that
necessary to keep the rat’s head above the water.
Three raters blinded to treatment conditions scored the aforementioned behaviors using a
time-sampling technique (Detke et al., 1995; Lucki, 1997) wherein the predominant behavior
over 60 - five second periods (300-s test) was recorded, producing sums for each behavior
(swimming, climbing, immobility). Once inter-rater reliability was within 20%, each rater scored
an assigned batch of animals (N = 16, 4 rats from each condition) to reduce the likelihood of
obscured results due to inter-rater variation. Antidepressant-like effects are indicated when
immobility in drug-treated rats is significantly less than that of control rats (saline). Active
behaviors (swimming and climbing) can be further distinguished by neurotransmitter action. For
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example, drugs primarily increasing serotonin, such as fluoxetine, increase swimming behavior
without increasing climbing. Respectively, drugs known to increase noradrenergic signaling
increase climbing but not swimming behavior (Slattery & Cryan, 2012). To ensure that changes
in immobility or mobility (swimming, climbing, etc.) from the FST were valid, locomotor
activity was assessed immediately prior in the OFT. As noted above, only when locomotor
activity is unchanged can changes in behaviors in FST be considered valid.
Dosing and Testing Regimen
All rats assigned to the aforementioned treatment groups received intraperitoneal (IP)
injections of either psilocybin, or vehicle once every three days for 48 days with two days
between each dose (Table 1). Forty-eight hours after the first set of eight doses (i.e., 24 days),
animals were tested in the L/D and OFT behavioral testing paradigms. The second set of eight
doses (i.e., days 25-48) were executed identically to the first set of behavioral tests with the
addition of the FST occurring immediately after the OFT. All three tests occurred 48 hours after
the last dose (16th injection/session, day 46). Rats underwent the OFT and FST one additional
time (day 58) two weeks after the second set of behavioral tests (day 48) to identify any
sustained effects of psilocybin. All animals were euthanized after the last behavioral test day as
per specification from the Guide for the Care and Use of Laboratory Animals (2011).

26

Table 1

Data Analysis
Dependent variables were plotted as treatment group means ± standard error of the mean
(SEM). GraphPad Prism version 7 (GraphPad Software, San Diego, CA) was used to analyze
and graph data. Data analyses were performed by experimenter blinded to treatment conditions.
Scores from the L/D test were analyzed with a two-way ANOVA with replication to assess the
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main effects of treatment and test day. Similarly, a two-way repeated measures ANOVA was
used with the treatment condition (PSI dose) as the between-subjects factor and time (1 min time
bins) as within-subjects factor for behaviors measured in the OFT. As no difference was
observed between treatment groups at any time points, time spent in center, total distance, and
stereotypy counts were summed for each rat’s 30-minute session and then averaged for each
treatment group and each OFT test conducted. Averages were analyzed two-way repeated
measures ANOVA (treatment, test number), followed by a Holm-Sidak for multiple
comparisons, if applicable. A select number of FST videos were recorded by all three raters to
determine inter-rater reliability coefficients. Inter-rater correlation coefficients calculated for
FST scores were found to be strong (>0.8). Three separate two-way repeated measures ANOVA
were used to assess the effects of drug treatment group and test day for each of the three recorded
behaviors recorded in the FST (immobility, swimming, and climbing). Alpha was set at .05 and
Holm-Sidak post hoc tests were used where applicable.

RESULTS
Light/Dark Box Test
None of the dependent measures assessed in the Light/Dark box showed a statistically
significant treatment effect. Specifically, psilocybin did not affect latency to enter the light
compartment (Fig. 1A), time spent in either compartment (Fig. 1B), total entries into the light
compartment (Fig. 1C), or time spent exploring the light compartment (Fig. 1D). Although the
main effect of treatment was non-significant, the latency to enter the light compartment was
significantly reduced in the second L/D test on day 48 (M = 14.59, SD = 5.79) compared to the
first L/D test on day 24 (M = 31, SD = 10.76), (F(1, 44) = 7.44, p = .009). A Holm-Sidak’s
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multiple comparison test indicated that the average latency to enter the light compartment during
the second test (M = 10.64, SD = 12.03) was significantly reduced from the first test (M = 45.94,
SD = 12.03) in the group treated with 0.1 mg/kg psilocybin (p = 0.02) (Fig. 1A). No other
statistically significant differences were observed within groups across test exposures.

Figure 1. Light dark test (L/D). Average time to enter light (panel A), time spent in the light
compartment (panel B), number of entries into the light compartment (panel C), and average
number of beam breaks (activity) on the light side (panel D) across all drug conditions, and test
day 24 (48 h post eighth injection) and day 48 (48 hours following 16th injection). Error bars
represent SEM. *p <.05.
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Open Field Test (OFT)
A two-way repeated measures ANOVA did not reveal a significant main effect of
treatment for any of the measures recorded (time spent in center, total distance traveled,
stereotypy, nor less notable behaviors: total time spent moving, vertical or horizontal activity). A
statistically significant effect of test number was observed for time spent in center [F(2, 88) =
17.28, p < .0001]. As presented in Figure 2 panel A, Holm Sidak’s multiple comparisons test
indicated that the average total time spent in center was significantly more in the second (p < .05)
and third test (p < .001) compared to the first test exposure (day 24) in rats in the 0.05 mg/kg
treatment group. Rats administered 0.1 mg/kg spent significantly more time in the center during
the last test exposure (day 58) compared to the first test exposure (day 24) (p = .005). Total
distance traveled (cm), the primary measure of locomotor activity assessed immediately prior to
FST, was non-significant for both factors (treatment, p = .757; test exposure, p = .134) (Fig. 2B).
The main effect of test exposure/time yielded an F ratio of F(2, 88) = 30.72, p < .0001,
indicating that the mean number of stereotypy counts was significantly less during the second
(day 48) and third (day 58) test exposures than from the first test exposure (day 24) in the vehicle
treated rats (p < .0001; p = .0006), 0.05 mg/kg (p = .0006; p = .0023), and 0.1 mg/kg treated
psilocybin rats (p = .006; p = .04) (Fig. 2C). However, the main effect of drug treatment between
groups was non-significant. Time spent in the center of the apparatus, distance traveled, and
stereotypy counts calculated into 60 sec. time bins over each 30 minute OFT exposure are
depicted in Figure 3. Statistical analysis of scores across each measure did not reveal a
significant effect of drug treatment group. The main effect of time interval was significant for
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each measure at each test exposure, as such that locomotor activity and stereotypy both
decreased over time.

Figure 2. Open Field Test – locomotor activity assessment. Total time spent in the center of the
apparatus (panel A), distance traveled (cm) (panel B), and number of repetitive beam breaks as a
measure of stereotypy (panel C) were calculated for each subject and are displayed as averages
(±SEM) for each drug condition, and test day (day 24, 48, and 58). Day 24 (D24) occurred 48 h
after the eighth injection, day 48 (D48) occurred 48 hours after the 16th injection, and day 58
(D58) occurred 12 days post last injection (16th injection). Error bars represent SEM. *p <.05,
**p <.01, ***p <.005, ****p <.001.

31

Figure 3. Open Field Test – locomotor activity assessment. Average time spent in the center of
the apparatus (left column), average distance traveled (cm) (center column), and the average
number of repetitive beam breaks as a measure of stereotypy (right column) averaged into 1
minute time bins across the 30 minute OFT session for all drug treatment groups, and test days.
Day 24 (top row), 48 (middle row), and 58 (bottom row). Error bars represent SEM.

Forced Swim Test (FST)
None of the measures assessed in the FST (immobility (Fig. 4A), swimming (Fig. 4B), climbing
(Fig. 4C)) demonstrated a statistically significant difference between treatment group [F(3, 44) =
.32, p = .81; F(3, 44) = .14, p = .94; F(3, 44) = 1.30, p = .29]. Statistically significant differences
were observed between test day for swimming [F(1, 44) = 8.69, p = .0051] and climbing [F(1,
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44) = 6.84, p = .01], but not for immobility [F(1, 44) = 1.11, p = .30]. Holm-Sidak’s multiple
comparison test did not indicate any significance within group differences between the first FST
on day 48 and the second FST test exposure on day 58. Group means for each FST behavior are
presented in Table 2.

Figure 4. Forced Swim Test (FST). Effect of treatment on immobility (A), swimming (B), and
climbing (C) behavior in the FST. Sixty counts of behavior from 5 second bins averaged for each
treatment group during 5 minute test (y-axis). Treatment groups are presented in sequential order
for each behavior and test day (48 and 58) so that the initial bar (red) represent the saline control
animals, second bar (purple) represent 0.025 mg/kg, third bar (green) 0.05 mg/kg, and fourth bar
(blue) 0.1 mg/kg psilocybin treated rats on each test day (48 and 58). Error bars represent SEM.
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Table 2
Immobility, Swimming, and Climbing at Test Day 48 and Day 58 For All Treatment Groups
Vehicle

0.025 mg/kg

0.05 mg/kg

0.1 mg/kg

Row

Variable

M

SD

M

SD

M

SD

M

SD

M

SD

Immobility
Day 48
Day 58
Column

20.92
18.25
19.58

12.99
11.86
12.83

23.25
22.00
22.63

11.73
12.40
11.83

21.33
21.17
21.25

11.58
11.33
11.20

24.42
23.42
23.92

10.80
14.24
12.37

22.48
21.21
21.84

1.64
2.18
1.86

Swimming
Day 48
Day 58
Column

22.50
28.33
25.42

11.46
9.58
10.75

25.58
28.33
26.96

8.34
11.54
9.95

24.50
28.08
26.29

10.69
11.98
11.26

22.83
26.17
24.50

9.14
13.79
11.57

23.85
27.73
25.79

1.45
1.05
1.07

Climbing
Day 48

16.58

7.89

11.17

6.78

14.17

4.64

12.75

5.62

13.67

2.30

Day 58

13.42

6.88

9.667

8.34

10.75

6.84

10.42

7.01

11.06

1.63

15.00

7.42

10.42

7.47

12.46

5.98

11.58

6.33

12.36

1.95

Column

Note. Averages were calculated from a total of 60 five-second bins counts for each rat in each treatment
group.

DISCUSSION
The therapeutic benefits of psilocybin in clinical settings have been consistently reported
in short and long-term treatment outcomes of depression and anxiety disorders (Carhart-Harris et
al., 2016, 2018; Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016; Rucker et al., 2016).
Despite such favorable outcomes, a percentage of individuals, albeit low (<30%), required
additional psilocybin assisted therapy after the first session for continued relief from symptoms
of depression and anxiety (Carhart-Harris et al., 2018). Additionally, high psilocybin doses are
known to produce distortions in sensory perceptions, often accompanied by negative
stigmatization, potentially deterring suitable candidates to the treatment option all together
(Dahlberg et al., 1968; Anderson et al., 2019a). Additionally, high psilocybin doses may be
counter therapeutic for some individuals (Hasler et al., 2004; Nielen et al., 2004), while low
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doses may be more safely tolerated. Low, subthreshold psilocybin doses, often referred to as
microdoses, do not produce such profound states of altered consciousness (Yanakieva et al.,
2019), and yet, have been reported to have similar cognitive and emotional benefits to those
reported from clinical studies with higher doses (Anderson et al., 2019b; Cameron et al., 2020;
Prochazhova et al., 2018).
Human research with psychedelic substances is often unavoidably entangled with a
myriad of subjective effects, in addition to other potentially confounding variables. Results from
a prospective survey based design found that although participants reported reductions in state
anxiety and depressive symptoms, greater baseline expectancy scores were correlated with larger
change scores of anxiety (r = 0.22, p = .025) and depression (r = -0.263, p = .009) at the study
endpoint. However, 84.9% of participants in the Kaertner et al. (2021) study had taken a classic
psychedelic at least once before, with 29.6% of participants reporting to have experimented with
microdosing prior to the study (Kaertner et al., 2021), which could have potentially skewed
expectancy scores due to preexisting biases. Animal models provide objective behavioral
measures predictive of human disorders, such as depression and anxiety, absent of confounding
variables such as “placebo effect” that are difficult to eliminate in human studies. Elimination of
such confounding variables is essential to elucidate the underlying behavioral and
neurobiological mechanisms that may mediate the effects of psilocybin noted in human studies.
The lack of any significant treatment effect was contrary to our hypothesis that chronic
intermittent low dose (CILD) psilocybin treatment would produce antidepressant and anxiolyticlike effects in rats. Significant differences between test sessions, conducted at different points
during the study (day 24, 48, 58), were observed in some, but not all behavioral paradigms or
treatment groups, and should be interpreted with caution. Specifically, rats treated with 0.1
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mg/kg psilocybin took less time to enter the light side in the L/D test during the second test on
day 48 compared to the first test on day 24. Although not significantly different from the salinetreated group, rats treated with 0.1 mg/kg demonstrated an anxiolytic-like effect after 16
psilocybin injections when comparing the average latency scores of the group after eight
injections (day 24). It should be noted that animals treated with 0.1 mg/kg had the highest
average latency score on day 24, complimented by the lowest average latency time on day 48
(see Figure 1A.). No significant differences were observed with latency to enter scores from the
first test to the second test in any other treatment group.
A similar pattern was observed in the OFT, wherein animals treated with either 0.05
mg/kg or 0.1 mg/kg psilocybin spent significantly more time in the center of the apparatus,
indicative of an “anxiolytic-like” effect, in a later test day compared to an earlier one, while the
lowest dose group (0.025 mg/kg) and saline-treated animals did not spend a significantly
different amount of time in the center of the apparatus from one test day to another throughout
the study. Specifically, both groups receiving the higher of the “sub-perceptual” doses
demonstrated an increased anxiolytic-like effect from day 24 to day 58 (12 days post final
psilocybin dose), suggesting that the additional eight doses of psilocybin may have produced the
observed within-group significance. Interestingly, only rats treated with 0.05 mg/kg spent
significantly more time in the center of the apparatus on day 48 compared to day 24, while rats
treated with 0.1 mg/kg spent significantly more time in the center 12 days after the final (16th)
psilocybin injection compared to the first test (day 24, 48 hours after the 8th injection). It is
possible that the anxiolytic/antidepressant-like effects of psilocybin may not be apparent for a
period of time after the last injection. Rats assessed in the FST seven to 35 days and in the EPM
40-41 days after a single injection of 1 mg/kg psilocybin demonstrated robust anxiolytic and
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antidepressant-like effects (Hibicke et al., 2020), whereas rats assessed 24 to 48 hours after a
single dose did not (Horsley et al., 2018; Jefsen et al., 2019). One interpretation of these
divergent findings is that a longer delay between treatment and behavioral assessment may be
required to observe significant treatment effects. This interpretation could also account for the
seemingly delayed full effect observed within groups at day 58 (12 days post-injection) in the
current study.
As in the L/D and OFT, rats treated with psilocybin did not produce any positive, or
negative, behavioral effects in the FST, as determined by the amount of time counted as
immobile or active (swimming or climbing). Results between groups and within groups from
both test days were relatively indistinguishable from one another (see Figure 4). The lack of
antidepressant-like actions of low-dose psilocybin in the FST not only contradict anecdotal and
subjective reports from human users (Anderson et al., 2019b; Cameron et al., 2020; Ultimate
Guide to Microdosing Mushrooms, n.d), but also contradict results from single high dose
psilocybin treatment paradigms using the FST (Hibicke et al., 2020). Additionally, CILD with
the psychedelic DMT produced antidepressant-like effects (reduced immobility and increased
swimming) in the FST in rats administered 10% of a previously identified “hallucinogenic”
DMT dose (Cameron et al., 2019) which used a similar scaling to the psilocybin doses assessed
in the current study.
It is noteworthy that researchers and assistants blinded to treatment assignment noted
observable group differences in rat behaviors during handling and FST video coding.
Surprisingly, these casual observations were not predictive of objectively scored test results.
Researchers in charge of handling, injecting, and implementing behavioral tests noted changes in
the rat behaviors after the first injection, which became more pronounced after the third
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injection. For example, on day 10 of the experiment, one researcher noted that rats in what was
identified as the 0.05 mg/kg group “felt less tense before, during, and after injections” and
appeared to engage in more self-grooming and resting in comparison with saline group which
appeared to remain relatively “tense” (rigidity of muscles) and “on alert” throughout the study.
Another researcher remarked on day four, “these two are chilling out” in response to rats A51
and A52, assigned to the 0.05 mg/kg treatment group. Both researchers that interacted in-person
with rats as well as two of three assistants who coded FST videos correctly suspected which rats
were assigned to the saline-treated group. Interestingly, the researchers had slightly more trouble
identifying which rats were assigned to the 0.1 mg/kg treatment group. In fact, on day 24 after
the first set of tests, researchers presumed that rats in group A (0.05 mg/kg) were assigned to the
highest dose treatment and that rats in group D (0.1 mg/kg) were treated with the second highest
dose based on observations of posture, coat appearance, and temperament during placement and
removal of rats from the test apparatus. Researchers deliberated over whether group A or D was
the 0.1 mg/kg treated group for the remainder of the study, noting that rats in group D appeared
to display greater within group variability compared to those in group A. Based on these causal
observations, a more systematic and objective evaluation of temperament and grooming
behaviors following psilocybin treatment warrants further investigation. Grooming, especially, is
known to be modulated by conditions used to provoke anxiety and depression-like states and
traits in rodents (Estanislau, 2012; 2013; Kalueff & Tuohimaa, 2005; Veloso et al., 2016).
In addition to assessing CILD psilocybin for anxiolytic and antidepressant-like effects,
the current study sought to investigate if long-term use of psilocybin on a chronic intermittent
dosing schedule would increase behaviors related to psychosis, anxiety, or depression in rats.
Very little has been investigated in regards to the long-term use of psilocybin at doses reported
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by human users (Fadiman, 2011; Ultimate Guide to Microdosing Mushrooms, n.d) and rodent
models of chronic psychedelic use have conflicting results. On one hand, chronic administration
of the psychedelic LSD at high a dose was found to increase stereotypy, locomotor activity,
anhedonia, and decrease social interaction in rats treated for three months (Marona-Lewicka et
al., 2011), while another study using bulbectomized rats found chronic administration of LSD
over 11 days reversed depressive-like avoidance learning (Buchborn et al., 2014). Similarly,
Horsley and colleagues (2018) found that subchronic intermittent microdoses of psilocin
produced and trended toward producing anxiogenic profiles on the EPM (Horsley et al., 2018),
while the present study did not find any significant differences between treatment groups in the
L/D, OFT, or FST. If anything, results from the present study demonstrate an increase in
positively associated behaviors in the OFT (time spent in center) and L/D test (latency to enter)
within group when comparing results from tests after eight and 16 injections, and again 12 days
post last injection. Moreover, rats administered 0.05 or 0.1 mg/kg psilocybin engaged in less
stereotypy during the OFT after 16 injections than the first instance stereotypy was measured
after eight injections. A similar pattern was observed in saline-treated animals, suggesting that
the decrease in stereotypy between test sessions was not an effect of drug treatment but of
exposure to the OFT itself. Nevertheless, the observed reduction in negatively associated
behaviors (stereotypy) and increase in anxiolytic behaviors (time spent in center, latency to
enter), contrast findings from previous rodent studies that suggest sub-chronic treatment may
increase negatively associated behaviors indicative of anxiety or depression (Horsley et al., 2018;
Marona-Lewicka et al., 2011). Furthermore, a number of methodological differences between the
current study and that of Horsley et al. (2018) could account for divergent results. Horsley et al.
(2018) utilized a different test paradigm (EPM), different drug (psilocin) and different dosing
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regimen (three injections every 48 hours) from the current study. The total duration of treatment
required for anxiolytic or antidepressant effects may be a determining factor in the effects of
psychedelics, particularly in regards to sub-perceptual doses.
Limitations
Several limitations in the present study design may have hindered an adequate assessment
of antidepressant and anxiolytic-like effects of CILD psilocybin. For one, it is possible that the
doses selected did not adequately represent a “sub-perceptual” microdose in a rat. Forum posts,
websites, and how-to guides suggest that a microdose is typically between five and 10% of a full
hallucinogenic dose, but typically no more than 20% (Fadiman, 2011; Fadiman & Korb, n.d.;
Johnstad, 2018; Polito & Stevenson, 2019; Ultimate Guide to Microdosing Mushrooms, n.d).
With that in mind, doses were selected based on prior literature that identified a single high dose
of 1.0 mg/kg psilocybin to produce anxiolytic and antidepressant-like effects without impacting
locomotor activity (Hibicke et al., 2020), along with a drug discrimination study that found 20%
drug-appropriate responding following 0.125 mg/kg, and less than 10% following 0.02 and 0.04
mg/kg in rats trained to discriminate 1.0 mg/kg psilocybin (Koerner & Appel, 1982). Cameron et
al. (2019) found positive results in the FST after chronic intermittent treatment with 1 mg/kg
DMT, which is considered 10% of a hallucinogenic dose, and also results in 20% drug-paired
responding in rats trained to discriminate 10 mg/kg DMT (Gatch et al., 2009). Future
investigations may consider evaluating a positive control substance or dose known to produce
observable behavioral effects.
The most surprising results from the current study were those from the FST. Typical drug
regimens for the FST involve dosing subjects ~24 hours before the official swim test, meaning
that the pre-swim exposure occurs before any drug exposure (Slattery & Cryan, 2012). However,
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the current treatment timeline and test schedule was guided from previous published studies in
which rats were placed in pre-swim tests after receiving at least one injection of a psychedelic
substance and antidepressant-like effects were observed (Cameron et al., 2019; Hibicke et al.,
2020). In rats treated according to a similar dosing schedule with DMT, immobility was
significantly decreased and swimming behavior was significantly increased after 10 injections in
DMT-treated rats compared to controls (Cameron et al., 2019). Rats assessed in the FST once,
twice, or repeatedly every week after a single injection of 1 mg/kg psilocybin also displayed
similar patterns of antidepressant-like behavior (Hibicke et al., 2020).
Interestingly, behavioral counts (recorded from 5 sec bins over 5 minutes) of salinetreated controls in the current study are markedly different, especially for immobility, compared
to those reported by Cameron et al. (2019) and Hibicke et al. (2020). In fact, approximately half
of the scores (25-30) of saline-treated controls should be recorded as immobile when using the
modified FST with Sprague-Dawley rats (Slattery & Cryan, 2012), and even higher when using
strains with elevated stress responses such as the Wistar-Kyoto rat (Lopez-Rubalcava & Lucki,
2000; Rittenhouse et al., 2002). The average total time (counts) that saline-treated control
animals spent immobile was M = 19.58 (SD = 12.24), was markedly lower than previous
research and protocols led researchers to expect. Due to the unexpected difference in immobility
scores of saline-treated animals, results from the FST should be interpreted cautiously.
A possible explanation for the stark difference in observed immobility scores of vehicletreated animals from anticipated scores could be due to scoring differences among raters. From
the beginning, obtaining adequate inter-rater reliability among scorers was difficult. In particular,
raters tended to score passive swimming, only that necessary to keep head above water, as active
swimming or climbing. Multiple individual and group virtual meetings were required to obtain
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inter-rater reliability scores that were within 20%. To help reduce inter-rater variation that may
skew results, each rater was solely responsible for scoring 16 FST videos, 4 videos from each
condition. Even so, raters completed scoring at various time points over the course of three
months. One or more raters may have completed the bulk of their scoring at a later time,
therefore further from initial training, resulting in scoring that was not consistent with formal
instructions. Aside from performing uniform inter-rater reliability checks in the future, camera
placement should be reconsidered. Slattery and Cryan (2012) suggest that placing cameras above
the swim tanks, filming from an aerial point of view may lead to more accurate and consistent
scoring. Raters are less likely to score passive swimming as active behaviors. Immobility,
swimming and climbing can be more precisely and simply operationally defined from an aerial
view than from a horizontal plane. For example, from an aerial perspective, the cylinder can be
divided into quadrants, and horizontal movements through the cylinder and crossing into
adjacent quadrants can be scored more easily. While the same two criteria were kept for scoring
on a horizontal plane, additional descriptions and criteria had to be added to the operational
definitions of swimming and climbing in order to get consistent IOA. Swimming was considered
to have occurred if rats' forearms moved in such a way to cause the rat to move from one area to
another and did not appear to be “essential” forepaw movement to keep head above water.
Additionally, the dorsal side of the rat should be more superficial to the surface during
swimming, while posterior side should be further from the surface with the ventral side more
perpendicular to the surface of the water. Although studies have successfully scored videos from
horizontal/lateral views (Hibicke et al., 2020), future studies may find that placing cameras
above cylinders may result in easier, more consistent scoring between researchers.
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The overall lack of statistical significance between psilocybin treated animals and salinetreated control animals may have been due to a ceiling effect. Future studies may benefit from
the use of animals genetically predisposed to depression or the implementation of
pharmacological or behavioral approaches such as chronic mild stress paradigms to assess the
effects of chronic intermittent low-dose psilocybin for a more ecologically valid model of
depression in rodents that would reduce the risk of a ceiling effect. Psilocybin rapidly restored
sucrose preference, a presumed measure of anhedonia in rodents, in chronically stressed mice but
not in saline-treated control mice. Interestingly, mice determined to be “stress-resilient” (sucrose
preference maintained above 70% after a 14 day chronic multimodal stress paradigm) did not
display significant changes in sucrose preference after psilocybin injection (Hasselgrave et al.,
2021). Combined with the uncharacteristically low levels of immobility seen in saline-treated
rats in the present study, antidepressant and anxiolytic effects of psilocybin may have been
masked by animals that would have otherwise been determined as “resilient”. Future studies
should utilize pharmacological or environmental stressors to create a more ecologically valid
model of depression in rodents and remove animals that would otherwise be classified as
“resilient” and therefore mask potential effects of CILD psilocybin.
Conclusion
The apparent lack of anxiolytic or antidepressant-like effects of chronic intermittent low
dose psilocybin treatment in the present study suggests there may be distinct mechanistic and
behavioral effects between sub-threshold “microdoses” and higher hallucinogenic doses
previously assessed in similar behavioral assessments (Hesselgrave et al., 2021; Hibicke et al.,
2020). However, it is also possible that the rodent behavioral tests employed in the present study
were inadequate to detect antidepressant and anxiolytic effects reported by humans. Future
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investigations involving more complex behavioral models, such as operant tasks, as well as more
ecologically-representative rodent strains may be more appropriate to model the behavioral
effects of psilocybin “microdosing” reported in humans. Additionally, future studies should
examine neural indices and biomarkers implicated in depression and anxiety disorders, along
with those implicated in psychosis, to further evaluate the potentially negative and/or positive
effects of long-term administration of psilocybin which may prove difficult to assess with
behavioral assessments alone.
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